NewAmsterdam Pharma Company N.V.
NAMS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $1 | $0 | $0 |
| - Cash | $1 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $1 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 223.4% | -86.3% | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -530% | -1,255.2% | -21.8% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -530.3% | -1,255.8% | -22% | – |
| EPS Diluted | -2.56 | -2.15 | -1.11 | -3.34 |
| % Growth | -19.1% | -93.7% | 66.8% | – |
| Operating Cash Flow | -$0 | -$0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | $0 | -$0 |